Only three targeted therapy drugs, namely HER2 antibody (Trastuzumab)/HER2-antibody drug conjugate(T-DXd), VEGFR2 antibody (ramucirumab) and PD-L1 antibody (Pembrolizumab), were approved for advanced and metastatic GC when used in combination with chemotherapy. This evidence concerns the gene ERBB2 and gastric cancer.